BRPI0407096A - Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos - Google Patents

Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos

Info

Publication number
BRPI0407096A
BRPI0407096A BR0407096-8A BRPI0407096A BRPI0407096A BR PI0407096 A BRPI0407096 A BR PI0407096A BR PI0407096 A BRPI0407096 A BR PI0407096A BR PI0407096 A BRPI0407096 A BR PI0407096A
Authority
BR
Brazil
Prior art keywords
liposome
stable
filterable
sterile
antineoplastic drugs
Prior art date
Application number
BR0407096-8A
Other languages
English (en)
Inventor
Jia-Ai Zhang
Sydney Ugwu
Lan Ma
Gopal Anyrambhatla
Imran Ahmad
Original Assignee
Neopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Inc filed Critical Neopharm Inc
Publication of BRPI0407096A publication Critical patent/BRPI0407096A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TAXANO ENCAPSULADO EM LIPOSSOMO ESTáVEL, ESTéRIL E FILTRáVEL E OUTROS FáRMACOS ANTINEOPLáSICOS". A invenção fornece uma formulação de um ou mais fármacos antineoplásicos encapsulados em lipossomos que incluem pelo menos uma fração lipídica em adição ao fármaco antineoplásico na qual a composição é estável em uma solução aquosa em temepratura ambiente.
BR0407096-8A 2003-02-03 2004-02-03 Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos BRPI0407096A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44495803P 2003-02-03 2003-02-03
PCT/US2004/003157 WO2004069224A2 (en) 2003-02-03 2004-02-03 Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs

Publications (1)

Publication Number Publication Date
BRPI0407096A true BRPI0407096A (pt) 2006-01-24

Family

ID=32850955

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407096-8A BRPI0407096A (pt) 2003-02-03 2004-02-03 Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos

Country Status (9)

Country Link
US (1) US8298573B2 (pt)
EP (1) EP1596825A2 (pt)
JP (1) JP4711947B2 (pt)
KR (1) KR20050105451A (pt)
CN (1) CN1700906A (pt)
BR (1) BRPI0407096A (pt)
EA (1) EA200501252A1 (pt)
MX (1) MXPA05008284A (pt)
WO (1) WO2004069224A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
EA038653B1 (ru) * 2016-01-07 2021-09-29 Вестерн Юниверсити Оф Хелт Сайенсиз Составы для лечения рака мочевого пузыря
IL266198B2 (en) * 2016-10-28 2023-11-01 Servier Lab Liposomal formulation for use in cancer treatment

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419348A (en) 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4898735A (en) 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
US4812314A (en) 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
ATE77051T1 (de) 1988-03-04 1992-06-15 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US4952408A (en) 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
JPH06329533A (ja) 1993-05-20 1994-11-29 Kyowa Hakko Kogyo Co Ltd リポソーム製剤の製造法
US5554382A (en) 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
JP3431222B2 (ja) * 1993-08-20 2003-07-28 ティーディーケイ株式会社 磁気記録媒体の製造方法
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
WO1995024201A1 (fr) 1994-03-11 1995-09-14 Yoshitomi Pharmaceutical Industries, Ltd. Preparation de liposomes
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5696153A (en) 1994-05-16 1997-12-09 Napro Biotherapeutics, Inc. Therapeutic regimen for treating patients
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US6066331A (en) 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
DE4430593C2 (de) 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
CA2205500A1 (en) 1994-11-18 1996-05-30 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5693336A (en) * 1995-06-07 1997-12-02 Nexstar Pharmaceuticals, Inc. Blood stable liposomal cyclosporin formulations
DE69620802T2 (de) 1995-09-12 2002-10-10 Liposome Co Inc Hydrolysierbare hydrophobe taxanderivate
WO1997033552A1 (en) 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US5756537A (en) 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
MX337149B (es) 1997-06-27 2016-02-15 Abraxis Bioscience Llc Nuevas formulaciones de agentes farmacologicos, metodos para su preparacion y metodos para el uso de los mismos.
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6461637B1 (en) 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
PL363618A1 (en) * 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
US20050123593A1 (en) * 2001-06-25 2005-06-09 Jonathan Thompson Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints

Also Published As

Publication number Publication date
CN1700906A (zh) 2005-11-23
EA200501252A1 (ru) 2006-02-24
US20060029658A1 (en) 2006-02-09
WO2004069224A2 (en) 2004-08-19
KR20050105451A (ko) 2005-11-04
JP2006516650A (ja) 2006-07-06
WO2004069224A3 (en) 2004-11-11
MXPA05008284A (es) 2006-03-21
US8298573B2 (en) 2012-10-30
EP1596825A2 (en) 2005-11-23
JP4711947B2 (ja) 2011-06-29

Similar Documents

Publication Publication Date Title
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR0207726A (pt) Sais farmacêuticos
BR0112495A (pt) Forma de dosagem, processo para a produção de uma forma de dosagem e uso da forma de dosagem
BR0210139A (pt) Composições farmacêuticas
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
ES2066896T3 (es) Forma oral de farmaco de lipidos.
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
CY1107672T1 (el) Φαρμακευτικες και/ή κοσμητικες συνθεσεις για τη θεραπεια εντοπισμενου αδιπικου ιστου και κυτταριτιδας
BR0102040A (pt) Uso de paclitaxel estabilizado com albumina para preparação de uma droga para o tratamento de tumores sólidos e a droga desse modo obtida
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
BR0116945A (pt) Uma preparação para prevenção de restenose
BR0202375A (pt) Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração
BRPI0510080B8 (pt) combinação farmacêutica e seu uso
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
BRPI0407096A (pt) Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
BR0111678A (pt) Composições medicinais contendo derivados de propenona
ES2195573T3 (es) Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion.
BRPI0414979A (pt) preparação sólida
AR029509A1 (es) Una composicion farmaceutica en base a un compuesto de platino (iv) y el uso de dicho compuesto para preparar medicamentos antitumorales
BRPI0510694A (pt) composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole
BR0215048A (pt) Composições farmacêuticas à base de derivados de azetidina
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.